摘要： Clinical trials of the United States biotech company Gilead Sciences' experimental drug Remdesivir have begun on Wednesday in Wuhan, Hubei province, the Clinical trials of the United States biotech company Gilead Sciences' experimental drug Remdesivir have begun on Wednesday in Wuhan, Hubei province, the center of the novel coronavirus outbreak.
周三，美国生物技术公司吉利德在研药物瑞德西韦在新型冠状病毒爆发的湖北省武汉市开始进行临床试验。
Experts hope this drug, along with others that have shown to be effective against the virus in animal tests, can also work well in actual human patients.
专家们希望瑞德西韦以及其他已经在动物试验中被证明对病毒有效的药物，也能有效治疗实际感染病毒的患者。
The Phase III trials have been approved by China's National Medical Products Administration and will be conducted by the China-Japan Friendship Hospital and the Chinese Academy of Medical Sciences on patients at the Wuhan Jinyintan Hospital.
瑞德西韦三期临床试验已获国家药品监督管理局批准，由中日友好医院和中国医学科学院在武汉金银滩医院开展。
The project will study a total of 761 patients in two trials -- one trial is to assess the drug's potency on 308 cases with mild or moderate infections, and the other is on 453 severely infected patients, Cao Bin, the head of the clinical trial and vice-president of the friendship hospital, said in a launch ceremony on Wednesday.
周三，瑞德西韦临床试验项目负责人、中日友好医院副院长曹彬教授在项目启动会上介绍，瑞德西韦临床试验拟入组761例患者，采用两组试验对照方法评估药物的效力，其中一组为308例轻、中症患者，另一组为453例重症患者。
Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity that has not been approved anywhere globally.
瑞德西韦是一种具有广谱抗病毒活性的核苷类药物，目前还没有在全球任何国家得到批准。
It has demonstrated effectiveness in vitro and in animal models against viral pathogens MERS and SARS, which are also coronaviruses and are structurally similar to the novel coronavirus from Wuhan.
它已经在体外和动物试验中证明了对病毒病原体MERS和SARS的有效性，它们也属于冠状病毒，在结构上类似于武汉的新型冠状病毒。
